IL128562A0 - Fatty acid treatment - Google Patents

Fatty acid treatment

Info

Publication number
IL128562A0
IL128562A0 IL12856297A IL12856297A IL128562A0 IL 128562 A0 IL128562 A0 IL 128562A0 IL 12856297 A IL12856297 A IL 12856297A IL 12856297 A IL12856297 A IL 12856297A IL 128562 A0 IL128562 A0 IL 128562A0
Authority
IL
Israel
Prior art keywords
fatty acid
acid treatment
treatment
dyspraxia
precursors
Prior art date
Application number
IL12856297A
Other languages
English (en)
Original Assignee
Scotia Holdings Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc
Publication of IL128562A0 publication Critical patent/IL128562A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL12856297A 1996-08-27 1997-08-26 Fatty acid treatment IL128562A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9617847.0A GB9617847D0 (en) 1996-08-27 1996-08-27 Fatty acid treatment
PCT/GB1997/002282 WO1998008501A1 (fr) 1996-08-27 1997-08-26 Utilisation d'acide arachidonique et/ou d'acide docosahexanoique dans la fabrication d'un medicament destine au traitement de la dyspraxie

Publications (1)

Publication Number Publication Date
IL128562A0 true IL128562A0 (en) 2000-01-31

Family

ID=10798969

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12856297A IL128562A0 (en) 1996-08-27 1997-08-26 Fatty acid treatment

Country Status (14)

Country Link
US (1) US6184251B1 (fr)
EP (1) EP0956011B1 (fr)
JP (1) JP2001504086A (fr)
KR (1) KR20000035924A (fr)
AT (1) ATE219670T1 (fr)
AU (1) AU738117B2 (fr)
CA (1) CA2263839A1 (fr)
DE (1) DE69713620D1 (fr)
GB (1) GB9617847D0 (fr)
IL (1) IL128562A0 (fr)
NO (1) NO990934L (fr)
NZ (1) NZ334260A (fr)
WO (1) WO1998008501A1 (fr)
ZA (1) ZA977686B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258846B1 (en) * 1999-06-01 2001-07-10 Drugtech Corporation Nutritional supplements
GB0016045D0 (en) * 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
TWI367753B (en) * 2003-03-27 2012-07-11 Suntory Holdings Ltd Composition for normalization of infradian rhythm
GB0311081D0 (en) * 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
FI20060154A7 (fi) 2003-08-18 2006-05-11 Btg Int Ltd Neurogeneratiivisten tilojen hoito
WO2005046668A1 (fr) * 2003-11-14 2005-05-26 Mochida Pharmaceutical Co., Ltd. Agent preventif/therapeutique pour traiter les troubles de la parole
EP1713463A4 (fr) * 2004-01-19 2009-03-18 Martek Biosciences Corp Dysfonctionnement ou d ficit de reelin et techniques associ es
GB0425932D0 (en) * 2004-11-25 2004-12-29 Btg Int Ltd Structured phospholipids
GB0504333D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Treatment of cytokine dysregulation
GB0504362D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
US20070166411A1 (en) * 2005-12-16 2007-07-19 Bristol-Myers Squibb Company Nutritional supplement containing long-chain polyunsaturated fatty acids
EP3539560A1 (fr) 2007-02-22 2019-09-18 Children's Hospital & Research Center at Oakland Formulations d'acides gras, et leurs procédés d'utilisation
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
CA2704371A1 (fr) * 2007-11-01 2009-05-07 Wake Forest University School Of Medicine Compositions et procedes de prevention et de traitement de maladies touchant des mammiferes
GB2460056A (en) * 2008-05-14 2009-11-18 Arab Science & Technology Foun Compositions comprising omega-6 fatty acids for use in treating schistosomiasis
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4595985A (en) 1984-08-10 1986-02-13 Sentrachem Limited Cancer treatment
GB8813766D0 (en) 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
FR2653972B1 (fr) 1989-11-07 1993-07-09 Perrier Sante Sa Phase grasse pour produits alimentaires et matieres alimentaires comparables a la creme contenant ladite phase grasse et leur procede de preparation.
GB9026648D0 (en) 1990-12-07 1991-01-23 Efamol Holdings Nutrition
GB9217780D0 (en) 1992-08-21 1992-10-07 Efamol Holdings Fatty acid treatment
GB9217781D0 (en) 1992-08-21 1992-10-07 Efamol Holdings Fatty acid treatment
DE4304394A1 (en) 1993-02-13 1993-09-02 Fresenius Ag Prepn. for nourishment of oncological patients - comprises fats formulation contg. oleic acid, alpha-linolenic acid, etc., and opt. carbohydrate and proteins
CA2119000A1 (fr) 1993-03-19 1994-09-20 David Frederick Horrobin Formulation pour fumeurs
CA2164291C (fr) 1993-06-09 2007-10-30 David John Kyle Methodes et compositions pharmaceutiques utiles pour le traitement de troubles neurologiques
GB9423625D0 (en) 1994-11-23 1995-01-11 Scotia Holdings Plc Fortified fruit juice

Also Published As

Publication number Publication date
AU738117B2 (en) 2001-09-06
ZA977686B (en) 1998-02-27
NO990934D0 (no) 1999-02-26
CA2263839A1 (fr) 1998-03-05
US6184251B1 (en) 2001-02-06
DE69713620D1 (de) 2002-08-01
ATE219670T1 (de) 2002-07-15
GB9617847D0 (en) 1996-10-09
JP2001504086A (ja) 2001-03-27
KR20000035924A (ko) 2000-06-26
WO1998008501A1 (fr) 1998-03-05
NO990934L (no) 1999-04-14
EP0956011A1 (fr) 1999-11-17
EP0956011B1 (fr) 2002-06-26
NZ334260A (en) 2000-08-25
AU4024797A (en) 1998-03-19

Similar Documents

Publication Publication Date Title
ZA977686B (en) Fatty acid treatment.
MX9709238A (es) Formulaciones farmaceuticas y de dieta para la profilaxis y tratamiento de trastornos gastrointestinales.
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
PL321848A1 (en) Cell adhesion inhibitors
HUP0000558A3 (en) Use of active d vitamin analogues for producing pharmaceutical composition for the treatment of prostatic diseases
LU91145I9 (fr)
IL121170A0 (en) Compositions for the treatment of dermatological disorders
IL162214A (en) Pyridine derivatives and pharmaceutical compositions containing the same
IL110943A (en) Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders
EP0458699A3 (en) Use of baclofen for the preparation of medicaments for the treatment of angina pectoris
IL141157A0 (en) Salt form of pantoprazole and pharmaceutical compositions containing the same
HUP9903166A3 (en) Medicinal compositions for the prophylaxis or treatment of arteriosclerosis
HUP9904317A3 (en) Use of 1-hydroxy-2-pyridones for producing pharmaceutical compositions suitable for the treatment of skin diseases
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
BG103260A (en) The application of 1-hydroxy-2-pyridons for the treatment of seborrheic dermatitis
IL111805A0 (en) Pharmaceutical compositions comprising dimeticone for the treatment of aphthae
BG102716A (en) Method for the treatment of cardiac insufficiency by means of formulations opposing the endotheline
ZA875847B (en) Pharmaceutical compositions for the treatment of occlusive vascular diseases
HUP9901247A3 (en) Use of naphthimidazole-, naphthoxazole- and naphthothiazole-diones for the preparation of pharmaceutical compositions treating diseases caused by vascular function deficiency
YU29600A (sh) Korišćenje ketolida za dobijanje farmaceutskih preparata za prevenciju trombičnih arterijskih komplikacija povezanih sa arterosklerozom
GB2204488B (en) Pharmaceutical compositions for the treatment or prophylaxis of skin disorders
GB9510162D0 (en) Compositions for the treatment of skin conditions
IL111804A0 (en) Pharmaceutical compositions comprising dimeticone for the treatment of constipation
MY138319A (en) 1,5-benzodiazepine derivatives
AU7079300A (en) Compositions and methods for the treatment of immune related diseases